The estimated Net Worth of Roberto Pedro Rosenkranz is at least $783 mil dollars as of 9 June 2020. Roberto Rosenkranz owns over 24,000 units of FibroGen Inc stock worth over $38,440 and over the last 10 years Roberto sold FGEN stock worth over $744,700.
Roberto has made over 17 trades of the FibroGen Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently Roberto exercised 24,000 units of FGEN stock worth $572,400 on 9 June 2020.
The largest trade Roberto's ever made was exercising 30,000 units of FibroGen Inc stock on 15 May 2019 worth over $494,700. On average, Roberto trades about 3,583 units every 69 days since 2014. As of 9 June 2020 Roberto still owns at least 96,100 units of FibroGen Inc stock.
You can see the complete history of Roberto Rosenkranz stock trades at the bottom of the page.
Roberto's mailing address filed with the SEC is C/O FIBROGEN, INC., 409 ILLINOIS ST., SAN FRANCISCO, CA, 94158.
Over the last 10 years, insiders at FibroGen Inc have traded over $188,593,537 worth of FibroGen Inc stock and bought 106,523 units worth $1,309,423 . The most active insiders traders include Rory B Riggs, Thomas B Neff, eJeffrey William Henderson. On average, FibroGen Inc executives and independent directors trade stock every 8 days with the average trade being worth of $6,963. The most recent stock trade was executed by Deyaa Adib on 12 June 2024, trading 22,123 units of FGEN stock currently worth $25,884.
fibrogen is a research-based biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics to treat serious unmet medical needs. the company has built upon its extensive research experience in fibrosis and hypoxia-inducible factor (hif) biology to generate clinical programs targeting multiple therapeutic areas. fibrogen's most advanced product candidate, roxadustat (fg-4592), is an oral small molecule inhibitor of hif prolyl hydroxylases (hif-phs), in phase 3 clinical development for the treatment of anemia in chronic kidney disease (ckd). our second product candidate, fg-3019, is a monoclonal antibody in phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (ipf), pancreatic cancer and liver fibrosis. for more information please visit: www.fibrogen.com.
FibroGen Inc executives and other stock owners filed with the SEC include: